Breye Therapeutics ApS: Financial statements 2025
CVR: 40279865
Source: annual report 2025, Danish Business Authority
01/04/2024 – 31/03/2025
Breye Therapeutics ApS (CVR 40279865) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -7,545,558 and a net result of DKK -89,139,846 compared with DKK -70,150,057 the year before. Equity in the 2025 report amounted to DKK -40,637,790. The company had 3 employees in the financial year.
- Gross Profit
- DKK -7,545,558
- Profit/Loss
- DKK -89,139,846
- Equity
- DKK -40,637,790
- Total Assets
- DKK 57,047,626
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -7.5 mio. | -89.1 mio. | -40.6 mio. | 3 |
| 2024 | - | -7.8 mio. | -70.2 mio. | 48.5 mio. | 2 |
| 2023 | - | -2.9 mio. | -14.6 mio. | 14.5 mio. | 1 |
| 2022 | - | -674 t. | -780 t. | -752 t. | 1 |
| 2021 | - | -68 t. | -290 t. | 28 t. | 1 |
Official annual report
How creditworthy is Breye Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Breye Therapeutics ApS
Breye Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ciana Therapeutics ApS and Visus Therapeutics ApS. The management consists of Ulrik Mouritzen. The board consists of Jimmy Arnold V Van Heusden (chair), Carl Johan Kördel, Chiara Rossana Maria Liberati and Gabriela Burian. The company's owners include Novo Holdings A/S, Visus Holding ApS and BII Holdings A/S. The company has 3 employees (2026). In 2026, the company reported a gross profit of DKK -7,655,438 and a net result of DKK -85,575,302 compared with DKK -89,139,846 the year before. Equity in the 2026 report amounted to DKK -126,213,092.